NDLI: The potential of 1018 ISS adjuvant in hepatitis B vaccines: HEPLISAV™ review.

Please wait, while we are loading the content...

HPV vaccination coverage among women aged 18-20 years in Germany three years after recommendation of HPV vaccination for adolescent girls: results from a cross-sectional survey.

Addressing heterogeneous parental concerns about vaccination with a multiple-source model: a parent and educator perspective.

Efficacy and safety of pentavalent rotavirus vaccine in Japan: a randomized, double-blind, placebo-controlled, multicenter trial.

Long-term anti-HBs antibody persistence following infant vaccination against hepatitis B and evaluation of anamnestic response: a 20-year follow-up study in Thailand.

Immunotherapeutic efficiency of a tetravalent Aß1-15 vaccine in APP/PS1 transgenic mice as mouse model for Alzheimer's disease.

The potential of 1018 ISS adjuvant in hepatitis B vaccines: HEPLISAV™ review.

Determining the validity of hospital laboratory reference intervals for healthy young adults participating in early clinical trials of candidate vaccines.

Effectiveness of seasonal influenza vaccine against clinically diagnosed influenza over 2 consecutive seasons in children in Guangzhou, China: a matched case-control study.

Public trust and vaccine acceptance--international perspectives.

Potential therapeutic anti-tumor effect of a Salmonella-based vaccine.

Impact of rotavirus vaccination in Australian children below 5 years of age: a database study.

The rise (and fall?) of parental vaccine hesitancy.

Dr. Google: what about the human papillomavirus vaccine?

Long-term persistence of immunity after vaccination of pre-adolescents with low doses of a recombinant hepatitis B vaccine.

Does a monovalent inactivated human rotavirus vaccine induce heterotypic immunity? Evidence from animal studies.

Progress on the research and development of inactivated EV71 whole-virus vaccines.

Concomitant administration of hepatitis A vaccine with measles/mumps/rubella/varicella and pneumococcal vaccines in healthy 12- to 23-month-old children.

How society should respond to the risk of vaccine rejection.

Reactogenicity and safety of a liquid human rotavirus vaccine (RIX4414) in healthy adults, children and infants in China: randomized, double-blind, placebo-controlled Phase I studies.

Utilizing health information technology to improve vaccine communication and coverage.

Association between microRNA polymorphisms and humoral immunity to hepatitis B vaccine.

Validity of medical record documented varicella-zoster virus among unvaccinated cohorts.

Acute immune thrombocytopenic purpura as adverse reaction to oral polio vaccine (OPV).

Story and science: how providers and parents can utilize storytelling to combat anti-vaccine misinformation.

Provider dismissal policies and clustering of vaccine-hesitant families: an agent-based modeling approach.

Immunogenicity and safety of three 2010–2011 seasonal trivalent influenza vaccines in Chinese toddlers, children and older adults: A double-blind and randomized trial

Negotiating vaccine acceptance in an era of reluctance.

Parental vaccine concerns, information source, and choice of alternative immunization schedules.

Overview: special focus vaccine acceptance.

Questionnaire for a biotech: NovaDigm Therapeutics.

Human Vaccines & Immunotherapeutics. Letter from the editor.

Year: 2013 Volume: 9 Issue: 7

Year: 2013 Volume: 9 Issue: 6

Year: 2013 Volume: 9 Issue: 5

Year: 2013 Volume: 9 Issue: 4

Year: 2013 Volume: 9 Issue: 3

Year: 2013 Volume: 9 Issue: 2

Year: 2013 Volume: 9 Issue: 1

Year: 2012 Volume: 8

The potential of 1018 ISS adjuvant in hepatitis B vaccines: HEPLISAV™ review.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Eng, Nelson F. Bhardwaj, Nitin Mulligan, Rebecca Diaz-Mitoma, Francisco
Description	Author Affiliation: Eng NF ( Advanced Medical Research Institute of Canada)
Abstract	Hepatitis B (HBV) virus infects the liver, and upon chronic infection, can cause liver cirrhosis and hepatocellular carcinoma. Despite universal vaccination programs against the virus, HBV still affects over 2 billion people worldwide, with over 240 million developing a chronic infection. While current alum-adjuvanted vaccines have shown efficacy in promoting seroprotection in healthy adults, 5-10% of immune-competent populations fail to achieve long-lasting seroprotection from these formulations. Furthermore, a large proportion of immunocompromised patients fail to achieve seroprotective antibody titers after receiving these vaccines. A novel vaccine candidate, HEPLISAV™, uses immunostimulatory sequences (ISS), in its formulation that helps induce a robust humoral and cell mediated immunity against HBV. In Phase III clinical trials, HEPLISAV™ has been shown to elicit seroprotective antibody titers with fewer immunizations. Similar safety profiles are demonstrated when compared with current HBV vaccines. For these reasons, HEPLISAV™ is an attractive vaccine to combat this global disease.
File Format	HTM / HTML
ISSN	21645515
e-ISSN	2164554X
DOI	10.4161/hv.24715
Journal	Human Vaccines & Immunotherapeutics
Issue Number	8
Volume Number	9
Language	English
Publisher	Taylor & Francis
Publisher Date	2013-08-01
Publisher Place	United States
Access Restriction	Open
Subject Keyword	Discipline Immunology Discipline Therapeutics Adjuvants, Immunologic Administration & Dosage Hepatitis B Antibodies Blood Hepatitis B Vaccines Immunology Oligodeoxyribonucleotides Adverse Effects Clinical Trials, Phase Iii As Topic Drug-related Side Effects And Adverse Reactions Epidemiology Pathology
Content Type	Text
Resource Type	Article
Subject	Immunology and Allergy Immunology Pharmacology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Chitosan: a promising safe and immune-enhancing adjuvant for intranasal vaccines.

Product review on the JE vaccine IXIARO.

A phase III single arm, multicenter, open-label study to assess the immunogenicity and tolerability of a pentavalent DTwP-HepB-Hib vaccine in indian infants.

The potential of 1018 ISS adjuvant in hepatitis B vaccines

Review of 10 years of marketing experience with Chinese domestic inactivated hepatitis A vaccine Healive®.

Immunogenicity and safety of a pediatric dose of a virosomal hepatitis A vaccine in healthy children in India.

Hepatitis B and A vaccination in HIV-infected adults: A review.

Immunogenicity and safety of hepatitis E vaccine in healthy hepatitis B surface antigen positive adults.

Effects of oral levamisole as an adjuvant to hepatitis B vaccine in adults with end-stage renal disease: a meta-analysis of controlled clinical trials.

The potential of 1018 ISS adjuvant in hepatitis B vaccines: HEPLISAV™ review.

Similar Documents

Chitosan: a promising safe and immune-enhancing adjuvant for intranasal vaccines.

Product review on the JE vaccine IXIARO.

A phase III single arm, multicenter, open-label study to assess the immunogenicity and tolerability of a pentavalent DTwP-HepB-Hib vaccine in indian infants.

The potential of 1018 ISS adjuvant in hepatitis B vaccines

Review of 10 years of marketing experience with Chinese domestic inactivated hepatitis A vaccine Healive®.

Immunogenicity and safety of a pediatric dose of a virosomal hepatitis A vaccine in healthy children in India.

Hepatitis B and A vaccination in HIV-infected adults: A review.

Immunogenicity and safety of hepatitis E vaccine in healthy hepatitis B surface antigen positive adults.

Effects of oral levamisole as an adjuvant to hepatitis B vaccine in adults with end-stage renal disease: a meta-analysis of controlled clinical trials.

The potential of 1018 ISS adjuvant in hepatitis B vaccines: HEPLISAV™ review.